Abivax (ABVX) Total Current Liabilities (2021 - 2026)
Abivax (ABVX) posted quarterly Total Current Liabilities of $72.9 million for Q1 2026, down 34.5% year-over-year from $111.2 million in Q1 2025, and down 0.68% quarter-over-quarter from $73.4 million in Q4 2025.
Abivax (ABVX) Total Current Liabilities (2021 - 2026) Analysis & Trends
Abivax's Total Current Liabilities history runs 6 years deep, the most recent figure standing at $72.9 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 34.5% year-over-year to $72.9 million; the TTM figure through Mar 2026 stood at $72.9 million (down 34.5% YoY), while the FY2025 annual figure was $73.4 million, down 26.97% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $72.9 million, down from $73.4 million in the prior quarter.
- The five-year high for Total Current Liabilities was $127.2 million in Q2 2025, with the low at $52.5 million in Q4 2022.
- The 5-year median for Total Current Liabilities is $92.1 million (2025), against an average of $90.4 million.
- The sharpest annual moves came in 2023 and 2026: Total Current Liabilities soared 85.85% in 2023, then sank 34.5% in 2026.
- Abivax's Total Current Liabilities stood at $52.5 million in 2022, then surged by 85.85% to $97.6 million in 2023, then climbed by 2.94% to $100.4 million in 2024, then decreased by 26.97% to $73.4 million in 2025, then declined by 0.68% to $72.9 million in 2026.
- Business Quant data shows ABVX's Total Current Liabilities at $72.9 million in Q1 2026, $73.4 million in Q4 2025, and $92.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | 72.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72.86 Mn |
| Dec 31, 2025 | 73.36 Mn |
| Sep 30, 2025 | 92.08 Mn |
| Jun 30, 2025 | 127.18 Mn |
| Mar 31, 2025 | 111.23 Mn |
| Dec 31, 2024 | 100.45 Mn |
| Jun 30, 2024 | 86.12 Mn |
| Dec 31, 2023 | 97.58 Mn |
| Dec 31, 2022 | 52.51 Mn |
| Dec 31, 2021 | 36.91 Mn |